All News
#EULAR2022 POS0210
RNA sequencing in 11 RA-ILD patients vs 9 RA pts
⭐️Distinct gene expression in RA-ILD with type 1 IFN response, neutrophil activation, and degranulation and CCR1 chemokine interactions
@RheumNow
@fahidalghanim https://t.co/FIrZfzZV1C
Eric Dein ericdeinmd ( View Tweet)
TNFi were going to unleash a TB wave
What has the biologic era really done for TB & opportunistic infx?
Hospitalised data from Western Australia post-2003:
TB actually not up (screening)
myocoses were up (no screening)
Dare I say it: screening works
OP0274 #EULAR2022 @RheumNow
David Liew drdavidliew ( View Tweet)
#EULAR2022 – Day 2 Report
A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon. The latter covering topics like sarcoidosis, Still’s disease, and fibromyalgia.
https://t.co/dpq5Het2rN https://t.co/NIfkjhHw86
Links:
Dr. John Cush RheumNow ( View Tweet)
#EULAR2022 POS0256 by @CaoilfhionnMD, @DrLisaCS, @JuliePaikMD from @HopkinsRheum
10% of pts seronegative for COVID antibodies after vaccination
⭐️Risk factors: Non-white, J&J vaccine, MMF, RTX, GC, combination Rx, not-withholding peri-vaccination immunosuppression
@Rheumnow https://t.co/Izd4QJlOWH
Eric Dein ericdeinmd ( View Tweet)
OP0280 WIN-lupus study eval if #SLE LN pts in remission can stop Rx. In pts who continued vs. stopped Rx: renal relapse 12% vs. 27%, p=0.08 and severe SLE flare 12 vs 32%, p=0.03; pts relapsing had inc baseline UPCR/SLEDAI score; +APS; lower lymphs/C3 . #EULAR2022 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
Torgashina et al Rituximab in Sjogrens ILD. ILD first manifestation of Sjogrens in 26%. Rituximab improvement in 37% and stabilisation in 47%. @RheumNow #EULAR2022 POS0710 https://t.co/CCnPVrTGfI
Richard Conway RichardPAConway ( View Tweet)
#EULAR2022 OP0278:
Increase in risk of CVA compared to general population ~1.2x risk
⭐️This is unchanged between the pre-biologic (1972-1998) and the post-biologic treatment era
⭐️Interesting finding: smoking rate same over time in RA, despite decr in Norway in gen pop
@Rheumnow https://t.co/r8QsJABfvx
Eric Dein ericdeinmd ( View Tweet)
Charles-Schoeman et al. ORAL Surveillance. PE risk factors - History VTE, antidepressant use, obesity, steroids, male, age, OCP/HRT. PPI protective @RheumNow #EULAR2022 POS0239 https://t.co/fDLKrpvpgI
Richard Conway RichardPAConway ( View Tweet)
Pan et al. SPI-62 (11beta-hydroxysteroid dehydrogenase inhibitor) minimises steroid side effects in animal studies. Now going on to a clinical trial in PMR. Exciting as steroid adverse events are a huge problem in PMR/GCA @RheumNow #EULAR2022 POS1332 https://t.co/NEoIx971jS
Richard Conway RichardPAConway ( View Tweet)
Can we predict VTEs from JAKi for RA at all?
Baseline elevated D-dimer pts who go on to develop VTE
(but not baseline CRP, so not just general inflamm)
Questions raised about effect modification for VTE following JAKi too. This story not yet done
OP0269 #EULAR2022 @RheumNow https://t.co/ErDcFpXXUl
David Liew drdavidliew ( View Tweet)
#EULAR2022 OP0277 MSK IRAE from Checkpoint inhibitors
⭐️118 pts w MSK complaints
76% w arthralgias/myalgias, 30% with inflammatory rheumatic features
Most grade 1/2, 2 grade 4 (myositis)
23 (19.5%) required d/c, time of resolution ~3 mos, 20% persistence at end of study
@RheumNow https://t.co/SINqmmjsLq
Eric Dein ericdeinmd ( View Tweet)
Leng et al. Tocilizumab biosimilar BAT1806/BIIB800 vs originator in MTX-IR RA. Not surprisingly they look the same. Great to see given negative clinical impact of recent supply problems with originator. @RheumNow #EULAR2022 POS0287 https://t.co/EqwINwcm7M
Richard Conway RichardPAConway ( View Tweet)
Tomelleri @tomelleri_a et al. GCA. Tocilizumab weekly x 1 year, then every other week x 1 year, then stop. 2 PMR flares during toc. 1 month post-stop 100% remission. 6 months post-stop 24% GCA flare! Some patients seem to need indefinite toc @RheumNow #EULAR2022 POS0266 https://t.co/8I5GQ08HDr
Richard Conway RichardPAConway ( View Tweet)
Long-term low-dose steroids for RA: can it be weaned?
Weaning after 2y of blinded add-on in RA:
either PNL 5mg/d or placebo
No substantial evidence of adrenal insufficiency
- symptoms same
- cortisol/ACTH same
It's never too late to wean the pred!
OP0270 #EULAR2022 @RheumNow https://t.co/jp2ZOlAEnb
David Liew drdavidliew ( View Tweet)
🧫 JAKi and NK
cells activation:
JAKi and particularly TOFA impacts NK cells:
*phenotype
*function
*impairs the control of proliferation of lung cancer and lymphoma cell lines
An explanation for the increase of cancer events in ORAL surveillance?
@RheumNow #EULAR2022 OP0265 https://t.co/LzMLdzcsDU
Aurelie Najm AurelieRheumo ( View Tweet)
MACE events no diff in German RA Rabbit registry of only humans shows #baricitinib and #tofacitinib vs #TNFis @RheumNow @eular_org #EULAR2022 OP0135 https://t.co/O8iOA7jpal
Janet Pope Janetbirdope ( View Tweet)
#EULAR2022 OP0274
Hospitalization for TB and other opportunistic infxn (OI) w inflamm joint disease:
⭐️9% with RA, 6% with PsA and AS in Western Australia
⭐️Decrease overall since 1985, but recent increase
⭐️Sharp rise of mycotic infections
⭐️No PJP, likely due to ppx
@Rheumnow
Eric Dein ericdeinmd ( View Tweet)
Low socioeconomic status should on the list as a high risk factor (#notJUSTrace) https://t.co/zikGGLISSN
TheDaoIndex KDAO2011 ( View Tweet)
Yoshimura et al. 10 year findings of TOMORROW study. Glucocorticoid use of even 2mg/day is fracture risk in RA! @RheumNow #EULAR2022 POS0631 https://t.co/c8uCdPzUiE
Richard Conway RichardPAConway ( View Tweet)
Visual symptoms in GCA: should we take it on face value?
@cmukhtyar group tertiary rheum/ophthal
n=350 consecutive GCA pts diagnosed (bx/PET)
visual symptoms 29%
ocular signs 13%
Not all symptoms = signs
No doubt not all symptoms of same concern
POS0810 #EULAR2022 @RheumNow https://t.co/TYHylpBhkN
David Liew drdavidliew ( View Tweet)